MYC inhibition induces metabolic changes leading to accumulation of lipid droplets in tumor cells

Proceedings of the National Academy of Sciences of the United States of America

Volumn 110, Issue 25, 2013, Pages 10258-10263

  Zirath, Hanna ^a   Frenzel, Anna ^a   Oliynyk, Ganna ^a   Segerström, Lova ^b   Westermark, Ulrica K ^a   Larsson, Karin ^a   Persson, Matilda Munksgaard ^c   Hultenby, Kjell ^a   Lehtiö, Janne ^d   Einvik, Christer ^e   Påhlman, Sven ^c   Kogner, Per ^b   Jakobsson, Per Johan ^a   Henriksson, Marie Arsenian ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b KAROLINSKA UNIVERSITY HOSPITAL   (Sweden)

^c LUND UNIVERSITY HOSPITAL   (Sweden)

^d SCIENCE FOR LIFE LABORATORY   (Sweden)

^e UNIVERSITY HOSPITAL OF NORTH NORWAY   (Norway)

Author keywords

Cancer therapy; Fatty acid oxidation; Mitochondria; Oxidative phosphorylation; Small molecule

Indexed keywords

FAT DROPLET; MYC PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CELL CYCLE ARREST; CONTROLLED STUDY; HUMAN; HUMAN CELL; LIPID METABOLISM; METABOLIC REGULATION; MOUSE; NERVE CELL DIFFERENTIATION; NEUROBLASTOMA; NONHUMAN; PRIORITY JOURNAL; PROTEIN PROTEIN INTERACTION;

CANCER THERAPY; FATTY ACID OXIDATION; MITOCHONDRIA; OXIDATIVE PHOSPHORYLATION; SMALL MOLECULE;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; CELL DIFFERENTIATION; CELL LINE, TUMOR; CELL PROLIFERATION; DISEASE MODELS, ANIMAL; ELECTRON TRANSPORT; FATTY ACIDS; HUMANS; LIPID METABOLISM; MICE; MICE, NUDE; MICE, TRANSGENIC; MITOCHONDRIA; NEUROBLASTOMA; PROTO-ONCOGENE PROTEINS C-MYC; RECEPTOR, TRKA; SIGNAL TRANSDUCTION; THIAZOLES; XENOGRAFT MODEL ANTITUMOR ASSAYS;

MUS MUSCULUS;

EID: 84879289434     PISSN: 00278424     EISSN: 10916490     Source Type: Journal    
DOI: 10.1073/pnas.1222404110     Document Type: Article

References (45)

1. Eilers M, Eisenman RN (2008) Myc's broad reach. Genes Dev 22(20):2755-2766.
2. Meyer N, Penn LZ (2008) Reflecting on 25 years with MYC. Nat Rev Cancer 8(12):976-990.
3. Vita M, Henriksson M (2006) The Myc oncoprotein as a therapeutic target for human cancer. Semin Cancer Biol 16(4):318-330.
4. Cairns RA, Harris IS, Mak TW (2011) Regulation of cancer cell metabolism. Nat Rev Cancer 11(2):85-95.
5. Dang CV (2012) Links between metabolism and cancer. Genes Dev 26(9):877-890.
6. Dang CV (2012) MYC on the path to cancer. Cell 149(1):22-35.
7. DeBerardinis RJ, Lum JJ, Hatzivassiliou G, Thompson CB (2008) The biology of cancer: Metabolic reprogramming fuels cell growth and proliferation. Cell Metab 7(1):11-20.
8. Dang CV (2011) Therapeutic targeting of Myc-reprogrammed cancer cell metabolism. Cold Spring Harb Symp Quant Biol 76:369-374.
9. Graves JA, et al. (2012) Mitochondrial structure, function and dynamics are temporally controlled by c-Myc. PLoS ONE 7(5):e37699.
10. Li F, et al. (2005) Myc stimulates nuclearly encoded mitochondrial genes and mitochondrial biogenesis. Mol Cell Biol 25(14):6225-6234.
11. Prochownik EV, Vogt PK (2010) Therapeutic targeting of Myc. Genes Cancer 1(6):650-659.
12. Sodir NM, Evan GI (2011) Finding cancer's weakest link. Oncotarget 2(12):1307-1313.
13. Felsher DW (2010) MYC inactivation elicits oncogene addiction through both tumor cell-intrinsic and host-dependent mechanisms. Genes Cancer 1(6):597-604.
14. Soucek L, et al. (2008) Modelling Myc inhibition as a cancer therapy. Nature 455(7213):679-683.
15. Maris JM (2010) Recent advances in neuroblastoma. N Engl J Med 362(23):2202-2211.
16. Edsjö A, Holmquist L, Påhlman S (2007) Neuroblastoma as an experimental model for neuronal differentiation and hypoxia-induced tumor cell dedifferentiation. Semin Cancer Biol 17(3):248-256.
17. Westermark UK, Wilhelm M, Frenzel A, Henriksson MA (2011) The MYCN oncogene and differentiation in neuroblastoma. Semin Cancer Biol 21(4):256-266.
18. Yin XY, Giap C, Lazo JS, Prochownik EV (2003) Low molecular weight inhibitors of Myc-Max interaction and function. Oncogene 22(40):6151-6159.
19. Guo J, et al. (2009) Efficacy, pharmacokinetics, tisssue distribution, and metabolism of the Myc-Max disruptor, 10058-F4 [Z, E]-5-[4-ethylbenzylidine]- 2-thioxothiazolidin-4-one, in mice. Cancer Chemother Pharmacol 63(4):615-625.
20. Knoepfler PS, Cheng PF, Eisenman RN (2002) N-myc is essential during neurogenesis for the rapid expansion of progenitor cell populations and the inhibition of neuronal differentiation. Genes Dev 16(20):2699-2712.
21. Brodeur GM (2003) Neuroblastoma: Biological insights into a clinical enigma. Nat Rev Cancer 3(3):203-216.
22. Weiss WA, Aldape K, Mohapatra G, Feuerstein BG, Bishop JM (1997) Targeted expression of MYCN causes neuroblastoma in transgenic mice. EMBO J 16(11):2985-2995.
23. Delmore JE, et al. (2011) BET bromodomain inhibition as a therapeutic strategy to target c-Myc. Cell 146(6):904-917.
24. Mertz JA, et al. (2011) Targeting MYC dependence in cancer by inhibiting BET bromodomains. Proc Natl Acad Sci USA 108(40):16669-16674.
25. Dobbins RL, et al. (2001) Prolonged inhibition of muscle carnitine palmitoyltransferase-1 promotes intramyocellular lipid accumulation and insulin resistance in rats. Diabetes 50(1):123-130.
26. Ibdah JA, et al. (2001) Lack of mitochondrial trifunctional protein in mice causes neonatal hypoglycemia and sudden death. J Clin Invest 107(11):1403-1409.
27. Zaugg K, et al. (2011) Carnitine palmitoyltransferase 1C promotes cell survival and tumor growth under conditions of metabolic stress. Genes Dev 25(10):1041-1051.
28. Lupu R, Menendez JA (2006) Pharmacological inhibitors of fatty acid synthase (FASN)-catalyzed endogenous fatty acid biogenesis: A new family of anti-cancer agents? Curr Pharm Biotechnol 7(6):483-493.
29. Santos CR, Schulze A (2012) Lipid metabolism in cancer. FEBS J 279(15):2610-2623.
30. Pizer ES, et al. (2000) Malonyl-coenzyme-A is a potential mediator of cytotoxicity induced by fatty-acid synthase inhibition in human breast cancer cells and xenografts. Cancer Res 60(2):213-218.
31. Choi CS, et al. (2007) Continuous fat oxidation in acetyl-CoA carboxylase 2 knockout mice increases total energy expenditure, reduces fat mass, and improves insulin sensitivity. Proc Natl Acad Sci USA 104(42):16480-16485.
32. Oberthuer A, et al. (2006) Customized oligonucleotide microarray gene expressionbased classification of neuroblastoma patients outperforms current clinical risk stratification. J Clin Oncol 24(31):5070-5078.
33. Liu Y (2006) Fatty acid oxidation is a dominant bioenergetic pathway in prostate cancer. Prostate Cancer Prostatic Dis 9(3):230-234.
34. Nieman KM, et al. (2011) Adipocytes promote ovarian cancer metastasis and provide energy for rapid tumor growth. Nat Med 17(11):1498-1503.
35. Fan Y, Dickman KG, Zong WX (2010) Akt and c-Myc differentially activate cellular metabolic programs and prime cells to bioenergetic inhibition. J Biol Chem 285(10):7324-7333.
36. Morrish F, et al. (2010) Myc-dependent mitochondrial generation of acetyl-CoA contributes to fatty acid biosynthesis and histone acetylation during cell cycle entry. J Biol Chem 285(47):36267-36274.
37. Yuneva MO, et al. (2012) The metabolic profile of tumors depends on both the responsible genetic lesion and tissue type. Cell Metab 15(2):157-170.
38. Reilly PT, Mak TW (2012) Molecular pathways: Tumor cells Co-opt the brain-specific metabolism gene CPT1C to promote survival. Clin Cancer Res 18(21):5850-5855.
39. Li S, et al. (2009) Transgenic expression of proximal tubule peroxisome proliferatoractivated receptor-alpha in mice confers protection during acute kidney injury. Kidney Int 76(10):1049-1062.
40. Funes JM, et al. (2007) Transformation of human mesenchymal stem cells increases their dependency on oxidative phosphorylation for energy production. Proc Natl Acad Sci USA 104(15):6223-6228.
41. Weinberg F, et al. (2010) Mitochondrial metabolism and ROS generation are essential for Kras-mediated tumorigenicity. Proc Natl Acad Sci USA 107(19):8788-8793.
42. Ward PS, Thompson CB (2012) Metabolic reprogramming: A cancer hallmark even warburg did not anticipate. Cancer Cell 21(3):297-308.
43. Kim J, Lee JH, Iyer VR (2008) Global identification of Myc target genes reveals its direct role in mitochondrial biogenesis and its E-box usage in vivo. PLoS One 3(3):e1798.
44. Morrish F, Neretti N, Sedivy JM, Hockenbery DM (2008) The oncogene c-Myc coordinates regulation of metabolic networks to enable rapid cell cycle entry. Cell Cycle 7(8):1054-1066.
45. Mo H, Henriksson M (2006) Identification of small molecules that induce apoptosis in a Myc-dependent manner and inhibit Myc-driven transformation. Proc Natl Acad Sci USA 103(16):6344-6349.